New Delhi, March 21 -- US pharma giant Eli Lilly has ventured into India with an anti-obesity and diabetes drug called Mounjaro. This development comes after the drug's approval from the Central Drugs Standard Control Organisation (CDSCO). This move seems to be strategically planned to address the ever-growing prevalence of obesity as well as type 2 diabetes in India. The World Health Organization states that there are 77 million people above the age of 18 years are suffering from diabetes (type 2) and nearly 25 million are prediabetics (at a higher risk of developing diabetes). Here's everything you need to know about Mounjaro for weight loss.

Mounjaro for weight loss: What is the new drug all about?

Mounjaro, the new anti-obesity and ...